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Macrophages are phagocytic cells involved in the immune response. They are derived
from circulating monocytes which differentiate into macrophages in the tissues. Despite small
phenotypic variations due to the different microenvironments of the tissues, all macrophages act
as the first line of defense against invading pathogens. 1
Macrophages primarily combat infection as a key component of innate immunity. They
are involved in both the initiation and maintenance of the inflammatory response, as well as the
initiation of the adaptive immune response. 1' 15 In innate immunity, macrophages establish the
inflammatory response. 1 Specifically, these cells phagocytose bound pathogens to destroy them
in phagolysosomes, and produce compounds, such as nitric oxide (NO) and reactive oxygen
intermediates (ROS), to aid in destruction of pathogens. Macrophages also produce and secrete
pro-inflammatory cytokines after being activated. Release of cytokines such as tumor necrosis
factor-a (TNF) or interleukin-6 (IL-6) enhances activation of phagocytes through autocrine and
paracrine signaling, and promotes recruitment of additional leukocytes to the site of infection.
TNF is also capable of directly killing extracellular microbes. 1' 12' 17 Through these innate immune
response activities the macrophages generally resist further replication of the pathogen and
reduce the total number of pathogens in the body. 3
Before a macrophage can perform these immune functions, it must be activated.
Activation may occur via binding of pro-inflammatory cytokines to cell surface receptors or by
recognition of pathogen-associated molecular patterns (PAMPs ). Lipopolysaccharide (LPS), a
component of gram-negative bacterial cell walls, is a common macrophage activating PAMP.
LPS binds to CD 14 and Toll-like Receptor 4 (TLR4) on the macrophage surface, stimulating a
cascade that results in the phosphorylation and subsequent degradation of cytosolic IKB. NF-KB
is thus released from IKB to enter the cell nucleus, and promote the transcription of proinflammatory genes. In response to the LPS signaling pathway, NF-KB promotes the
transcription of inducible nitric oxide synthase (iNOS), superoxide-producing enzymes and proinflammatory cytokines to combat the infection. 1' 3'9' 12 Other PAMPs stimulate additional
signaling cascades to activate transcription factors to start production of anti-microbial genes. 1•3
Catecholamines are small monoamines, such as NE which has been shown to be released
by the sympathetic nervous system during stress responses. 5•15•19 Although catecholamines are
predominantly derived from the neuroendocrine system, recent work has shown that NE and
dopamine are also synthesized by activated macrophages. 2,4 Catecholamines mediate their effects
by binding to the adrenergic receptors expressed on macrophages. Adrenergic receptors are
seven-transmembrane G-protein coupled receptors with cytoplasmic tails that interact with Gs
proteins. The activation of Gs proteins initiates signaling cascades that alter the immunological
activity level of activated macrophages in response to PAMPs. Primarily, stimulation of ARs
induces changes in NO and cytokine production correlating with the identity and concentration
of catecholamine to which the macrophages were exposed. 5 •15•19
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Adrenergic receptors can be divided into two major subgroups: a-AR and P-AR.
Generally, treatment of LPS-activated macrophages with P-ARs agonists has been demonstrated
to significantly reduce NO and inflammatory cytokine production. 14•17 This effect can be
abrogated by the addition of P-AR antagonists, indicating that the decrease is specific to
stimulation of the P-AR signaling cascade by catecholamines. 4 Kizaki et al. indicates that this
decrease in immunological activity is due to reduced release of NF-KB from IKB in the treated
macrophage's cytoplasm, preventing transcription of pro-inflammatory genes. 11
However, a small but significant body of primary literature has shown that stimulation of
the P-ARs of activated macrophages increases their immunological activity. A study by Szelenyi
et al. showed that treatment with isoproterenol, a P-AR agonist, increased TNF production by
macrophages activated with phorbol myristyl acetate. 17 It has also been demonstrated that the
enhancing effect of NE on macrophage production of NO can be abrogated by the addition of
propranolol, a P-AR antagonist. 3
There is also some disagreement in the primary literature regarding the role of a-ARs in
regards to regulating immunological activity of activated macrophages. In general, treatment
with a-AR agonists has been demonstrated to enhance the functions of activated macrophages.
Stimulation of a-ARs by clonidine during Mycobacterium avium or Toxoplasma gondii
infections significantly increases macrophage resistance to pathogen growth. 6•19 Likewise, UK14304 (an a-AR agonist) and low concentrations of NE have been shown to enhance TNF
production. This effect appears to be mediated at the transcriptional level, as increases in TNF
mRNA are seen in activated macrophages treated with NE. Antagonism of a-ARs with
yohimbine has been shown to significantly decrease the production ofTNF in response to a-AR
stimulation with a constant level of agonist, suggesting that the enhancement is mediated
exclusively by stimulation of the a-ARs. 9•15 However, another study found that stimulation of aARs with NE suppressed phagocytosis by macrophages. 7 Clonidine treatment has also been
shown to have no effect on NO production by activated macrophages, leading to the hypothesis
that a-ARs do not play a regulatory role in macrophages. 14 The discrepancies in these results
clearly point to a need to increase understanding of the role of a-AR signaling in macrophages.
Previous studies have generally demonstrated a distinctive pattern of regulation of
primary macrophages by adrenergic receptor stimulation. However, a complete characterization
of the regulation of RA W264.7 murine macrophages, an important cell culture model, has yet to
be performed. Additionally, a small but significant subset of current primary literature
contradicts the generally-accepted model of AR-mediated regulation of macrophages. These
functional differences may be due to changes in AR surface expression patterns in response to
LPS activation and/or stimulation by catecholamines, but little analyses has been performed in
this area. Therefore, further study is necessary to elucidate the roles and expression patters of
.
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In this study, AR surface expression patterns and regulation via AR-catecholamine
interactions were characterized. Macrophage function was shown to be regulated by
catecholamines through both a- and ~-ARs, as evidenced by corresponding alterations in
cytokine production. Treatment of activated macrophages with NE, a general catecholamine, or
fomoterol, a P-AR agonist, produced significant decreases in TNF and IL-6 secretion. The effecis
of clonidine, an a-AR agonist, produced less consistent results, but clonidine-mediated
enhancement of cytokine secretion appears to be mediated by a-AR signaling. LPS was shown to
noticeably change the surface expression ofboth types of ARs in RAW264.7 macrophages.
However, NE only influenced a-AR signaling. This data adds to the current model of
neuroendocrine regulation of macrophage-mediated immunity, specifically presenting functional
roles for a- and P-ARs.

Materials and Methods
RA W264. 7 Cell Culture
The RA W264. 7 murine macrophage cell line was used to model macrophage activity.
Cells were stored in liquid nitrogen until needed. After thawing, RA W264.7 macrophages were
cultured in RPMI-1640 complete media supplemented with 10% heat-inactivated fetal calf
serum, 1.5% sodium bicarbonate, 25 mM HEPES buffer, 1% minimal essential medium
vitamins, 1% glutamine, 1% nonessential amino acids, I 00 units/ml penicillin, and I 00 µg/ml
streptomycin. Cells were maintained in T25 -cm 2 or T 75 -cm2 tissue culture flasks in a humidified
incubator at 37°C, 5% CO 2 • Fresh media was added and cells were sub-cultured as needed to
maintain health.

Sandwich Enzyme-Linked Immunosorbent Assays
RA W264.7 murine macrophage cells were cultured to confluency in T75 -cm 2 flasks. For
experiments, cells were seeded into the wells of a 12-well tissue culture plate at a density of 1.5
x I 0 6 cells per well. Macrophages were treated with 5µM, 2.5 µM, 500nM and 50nM clonidine,
or 1µM, 500nM, 100nM and I 0nM fomoterol (FOM), or I µM, 500nM, 100nM and 10nM NE.
Additional studies were performed by treating cells treated with RS79948 (500 nM), an aadrenergic receptor antagonist, for 30minutes (3 7°C, 5% CO 2) prior to the addition of 5 µM, 2.5 µM,
500nM or 50nM clonidine. Control wells were left untreated and unactivated. All treatment
groups were then incubated for 30 minutes (37°C, 5% CO 2) before 30 ng/ml or 10 ng/ml LPS
was added to the media to activate the macrophages. The cells were incubated (37°C, 5% CO2)
for the appropriate times (TNF studies: 4 hours; IL-6 studies: 21 hours), then supematants were
harvested from each well and centrifuged at 11,000 rpm for 5 minutes. The pelleted debris was
discarded, and clean microfuge tubes of supernatants were frozen at -20°C until analysis.
An OptEIA Mouse TNF-a enzyme-linked immunosorbent assay (ELISA) kit (BD
Biosciences) was used to measure the quantity ofTNF secreted by each treatment group. The
ELISA was performed according to the manufacturer's instructions. A 96-well microtiter plate
was coated with 1:250 dilution ofTNF Capture Antibody, and incubated overnight at 4°C. The
wells were then washed three times with lx Wash Buffer, and blocked with Assay Diluent for 1

3

hour at room temperature. The wells were washed three times after the incubation. An aliquot of
each sample was added to wells in triplicate, and a standard curve of purified TNF (1000 pg/ml
to 15.6 pg/ml) was generated. The plate was incubated for 2 hours at room temperature, and then
washed five times. A 1:250 dilution of TNF Detection Antibody was added to each well for 1
hour at room temperature. After washing the wells five times, a 1:250 dilution of StreptavidinHRP secondary antibody was added to the wells. After a 30 minute incubation, the wells were
washed seven times with a 30-60 second soak in lx Wash Buffer between each wash. TMB
substrate was then added to each well, and the microtiter plate was incubated in the dark for 30
minutes. Stop solution was added to the wells, and the microtiter plate was read with a plate
reader at 450 nm with a correction reading at 570 nm. TNF concentrations in each treatment
group were calculated according to the absorbencies of the TNF standard curve.
An OptEIA Mouse IL-6 ELISA kit (BD Biosciences) was used to quantify the amount of
IL-6 secreted by each treatment group. This kit followed the same protocol as the TNF-a ELISA
Kit with a few notable changes. All antibodies used were specific for the IL-6 cytokine, and the
standard curve was prepared using dilutions of purified IL-6 (1000 pg/ml to 15.6 pg/ml).
Additionally, the Detection Antibody and Strepavidin-HRP were added in the same step.

Statistical Analysis
Concentrations ofTNF and IL-6 were calculated from their respective standard curves.
An ANOVA with a Tukey's Analysis using a p<0.05 was used to calculate significant changes
between sample treatments. All statistical analyses were performed with Graph Pad Prism
software.

Jmmunohistochemistry
RA W264.7 macrophages were cultured to confluency as previously described. Equal
quantities of cells were plated onto sterile cover slips placed in the wells of a 12-well tissue
culture plate. The cells were incubated (37°C, 5% CO 2) for 2-4 hours, then non-adherent cells
were removed by washing with lx PBS. Some experimental samples were treated with 1µM NE,
and incubated for 30 minutes at 37°C, 5% CO 2 • All experimental samples were activated with
100 ng/ml LPS. Control samples were not treated or activated. After a 4 hour incubation (37°C,
5% CO 2) cells were fixed with glyoxal (37°C, 15 minutes). Media was removed with three
washes using lx PBS, and cover slips were moved into a clean 12-well plate. The cells were then
blocked with a solution of 1% powdered milk in lx PBS for 30 minutes at room temperature
with gentle swirling. The cells were then washed three times, and incubated with either 1:25
mouse anti-a 28 adrenergic receptor antibody (Santa Cruz Biotechnology, Inc., sc-1479 or 1:50
mouse anti-~ 2 adrenergic receptor antibody (Santa Cruz Biotechnology, Inc., sc-570) in blocking
solution for 30 minutes at room temperature. After three more washes, a 1: 100 dilution of antimouse AlexaFluor 594 or 647 secondary antibody (Invitrogen) in blocking solution was added to
the corresponding wells. After a 30 minute incubation in the dark, the cover slips were washed
4

three times. The cover slips were mounted on slides using Prolong Gold Anti-Fade Mounting
Medium, and stored overnight at 4°C. Slides were sealed with nail polish and stored in the dark
at 4°C until analyzed. Samples with no antibodies, only primary antibody, only secondary
antibody, or serum with secondary antibody were prepared as controls to demonstrate the
specificity of tlw antibodies used.

Confocal Microscopy
Slides were viewed using a Leica SP2 Laser Scanning Confocal Microscope, at excitation
wavelengths of 561nm and 633nm for AlexaFluor 594 and 647 samples, respectively. Emission
was collected from 600 to 670nm for samples with AlexaFluor 594, and 650 to 750nm for
AlexaFluor 64 7. Gain and offset were set to the same levels for all collected images. Transmitted
light images were also collected from the confocal microscope. Leica Confocal Software was
used to collect images, and figures were prepared with Adobe Photoshop CS3.

Results
Treatment with high concentrations of NE reduces TNF secretion by RA W264. 7 macrophages
Macrophages produce pro-inflammatory cytokines to protect the host from bacterial
infections. The secretion of these inflammatory mediators is tightly regulated, such that
cytokines are only secreted in response to recognition of an on-going infection. This secretion
can be used in studies as a measure correlating to overall immunological activity level of
activated macrophages. 1 The secretion of cytokines has also been shown to be regulated by
signaling via ARs in activated macrophages, and can thus be used as a measure of the effects of
catecholamine treatment. 3 ' 14' 17
To study the ability of catecholamines to regulate macrophage function, we examined the
effect of treatment with the catecholamine NE on TNF production by activated RA W264. 7
macrophages. A sandwich ELISA was used to measure the amount ofTNF produced by the
LPS-activated macrophages pre-treated with NE. Analysis demonstrated that activation with LPS
elicits dose-dependent secretion ofTNF from RA W264.7 macrophages. At both concentrations
ofLPS, pre-treatment with lµM or 500 nM NE results in a significant decrease in the amount of
TNF secreted. Macrophages activated with 30 ng/ml LPS still show a significant decrease in
TNF secretion when treated with 100 nM NE, but the same NE concentration in the presence of
10 ng/ml LPS does not alter TNF secretion from baseline levels. At either LPS concentration,
addition of 10 nM NE has no effect on the production ofTNF by activated macrophages (Figure
1). As NE is known to bind both a- and P-ARs, it was expected that treatment would alter
cytokine secretion. 16 The reduction of TNF levels in response to treatment with high
concentrations of NE suggests that the P-AR signaling cascade was strongly activated. However,
low concentrations of NE did not alter TNF production so these studies do not provide evidence
for a-AR expression or function on RA W264.7 macrophages. Given these results, further
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research was needed to study the expression pattern of both types of ARs on RA W264.7
macrophages.
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Figure 1. Concentrations of TNF produced in response to NE treatment of activated RA W264.7 macrophages.
RA W264.7 macrophages were plated into 12-well tissue culture plates at a density of 1.5 x 106 cells/well. Cells were
then treated with 1µM, 500 nM, 100 nM or 10 nM NE for 30 minutes and then activated with 30 ng/ml or 10 ng/ml
LPS. Cells were incubated for 4 hours (37°C, 5%CO2) before supernatants were harvested. The concentration of
TNF in each sample was quantified using a TNF sandwich ELISA. Statistical analysis was performed using Graph
Pad Prism software.

Treatment with the /J-adrenergic receptor agonist fomoterol reduces cytokine secretion by
RA W264. 7 macrophages
The inhibitory effect of NE on TNF production is known to be mediated by stimulation
of P-ARs on RA W264. 7 macrophages. 3 To better understand the role of P-ARs in macrophage
activity, the macrophages were exposed to the specific P-AR agonist fomoterol (FOM) prior to
macrophage activation. After a 4 or 21 hour incubation period, TNF and IL-6 secretion,
respectively, was measured using an ELISA specific to each cytokine. ELISA analysis showed
that treatment with FOM significantly reduces the amount of both IL-6 and TNF secreted (Figure
2). A trend toward dose-dependent inhibition of IL-6 secretion is apparent from these studies
(Figure 2A and 2B). However, secreted IL-6 levels do not return to baseline levels at 10 pM
FOM, indicating that even extremely low concentrations of the P-AR agonist have a strong
negative effect (Figure 2B). These dose-dependent changes are only seen when RA W264.7
macrophages are activated with 30ng/ml LPS. When the cells are activated with 1Ong/ml LPS,
all the tested concentrations of FOM resulted in significantly decreased levels of secreted IL-6
(Figure 2A and B). Figure 2C demonstrates that FOM also effectively reduces TNF levels
produced by activated macrophages. Since FOM is known to selectively activate P-ARs, it can
be concluded that the cytokine decreases are due to catecholamine-mediated signaling through
the P-AR pathway.
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Figure 2. Concentrations of IL-6 and TNF produced in response to FOM treatment of activated RAW264. 7
macrophages. RA W264.7 macrophages were plated into 12-well tissue culture plates at a density of 1.5 x 106
cells/well. Cells were then treated with FOM (10 nM FOM - 10 pM) for 30 minutes and then activated with 30
ng/ml or 10 ng/ml LPS. Cells were incubated (37°C, 5%CO 2) for 21 hours prior to IL-6 ELISA analysis (A and B);
or 4 hours prior to TNF ELISA analysis (C). Statistical analysis was performed using Graph Pad Prism software.

Treatment with the a-adrenergic receptor agonist clonidine tends to enhance cytokine secretion
by RA W264. 7 macrophages
Primary macrophages also express a-ARs, which are generally believed to enhance the
activity of activated macrophages. 6' 9' 15' 19 However, a small portion of primary literature has also
suggested that stimulation of the a-AR may have no effect on or decrease macrophage
activity. 7' 14 To attempt to address this discrepancy in the literature, and to characterize the role of
a-ARs in regulating the function of RA W264.7 macrophages during an immune response, we
analyzed the production of TNF and IL-6 by LPS-activated macrophages treated with clonidine,
an a-AR agonist.
Macrophages were exposed to the specific a-AR agonist clonidine prior to macrophage
activation. After a 4 or 21 hour incubation period, TNF and IL-6 secretion, respectively, were
measured using an ELISA specific to each cytokine. Analysis of the ELISA data revealed that
clonidine stimulates increases in IL-6 production at specific concentrations. A dramatic
enhancement ofIL-6 secretion was seen when RA W264.7 macrophages were treated with 500
nM clonidine. This effect was found when the macrophages were activated with either
concentration ofLPS (30 ng/ml or 10 ng/ml). Additionally, macrophages activated with 10 ng/ml
7

LPS also showed a small but significant increase in IL-6 secretion in response to treatment with
50 nM clonidine (Figure 3A).
The effects of clonidine treatment on TNF secretion were less clear. Analysis of the
ELISA data indicated that TNF secretion is sometimes enhanced, while in other treatments it is
reduced or unaffected. Similar results were found with several repeated studies (Figure 3B).
Although signaling via the a-AR pathway typically induces a stimulatory effect, a few studies
have found that a-agonists can also negatively influence macrophage activity. 7•14 Further
research is necessary to determine what factors may influence the ambivalent behavior of a-AR
signaling.
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Figure 3. Concentrations of IL-6 and TNF secreted in response to clonidine treatment of activated RAW264. 7
macrophages. RA W264.7 macrophages were plated into 12-well tissue culture plates at a density of 1.5 x 106
cells/well. Cells were treated with 5 µM, 2.5 µM, 500 nM or 50 nM clonidine for 30 minutes and then activated with
30 ng/ml or 10 ng/ml LPS. Cells were incubated (37°C, 5%CO 2) for 21 hours prior to IL-6 ELISA analysis (A); or 4
hours prior to TNF ELISA analysis (B). Statistical analysis was performed using Graph Pad Prism software.

Treatment with the a-adrenergic receptor antagonist RS79948 inhibits the enhancement of
cytokine production seen in clonidine-treated, LPS-activated RA W264. 7 macrophages

In an effort to further characterize the role of a-ARs in the regulation of macrophage
immunological activity, RAW264.7 macrophages were treated with RS79948, an a-AR
antagonist, prior to treatment with clonidine. The addition of RS79948 blocks any signaling
through a-ARs, and thus abrogates any effects which are mediated by a-AR signaling.
ELISA analysis demonstrated that treatment of activated macrophages with 500 nM or 50
nM clonidine increases the concentration of cytokine secreted by the activated RA W264.7 cells
(Figures 3 and 4). The addition of RS79948 prior to clonidine treatment results in a significant
decrease in IL-6 production, returning the amount of secreted cytokine to levels equivalent to or
below those measured in untreated, activated macrophages (Figure 4A). Likewise, TNF secretion
is significantly impacted by blocking the a-AR pathway. RS79948 antagonism of the a-AR
pathway significantly decreases the amount of TNF secreted from the activated macrophages to
below positive control levels (Figure 4B). These results suggest that the positive effect of
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clonidine is mediated by signaling through the a-AR pathway, as blocking the stimulation of aARs abrogates this effect. Furthermore, the observation that cytokine levels decrease below that
of positive controls suggests that a-AR signaling may normally be involved in enhancing
macrophage activity in response to LPS activation.
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Figure 4. Concentrations ofIL-6 and TNF secreted in response to treatment of activated macrophages with clonidine
and the a-AR antagonist RS79948. RA W264. 7 macrophages were plated into 12-well tissue culture plates at a
density of 1.5 x 106 cells/well. Cells were then treated with 500 nM or 50 nM clonidine after a 30 minute incubation
with RS79948 and then activated with 10 ng/ml LPS. Cells were incubated (37°C, 5%CO 2) for 21 hours prior to IL6 ELISA analysis (A); or 4 hours prior to TNF ELISA analysis (B). Statistical analysis was performed using Graph
Pad Prism software.

Regulation of surface expression of /3-adrenergic receptors by LPS activation and NE exposure

In addition to studying the functional role of ARs, studies were also performed to
characterize the expression pattern of ARs on RA W264.7 macrophages. These
immunofluorescence studies were performed with mouse anti-P-AR primary antibody and antimouse IgG-AlexaFluor 594 conjugated secondary antibody. All labeled macrophages were
examined with a confocal microscope. Appropriate controls were also included to demonstrate
that each antibody was specific to its indicated protein, and to control for autofluorescence of the
RA W264.7 macrophages (data not shown).
Immunofluorescence reveals a distinctive pattern of P-AR surface expression in
RA W264.7 macrophages. Resting macrophages exhibit high levels of surface P-ARs (Figure 5
Al-A2'). However, the expression noticeably decreases in activated macrophages, as these
images are characterized by reduced staining intensity and less overall staining (Figure 5 B 1B2 '). NE treatment of activated macrophages does not visibly alter P-AR expression from the
reduced levels seen in activated macrophages (Figure C l-C2 '). These results suggest a
mechanism of cross-talk between pathways which regulates P-AR expression in response to
recognition of extracellular LPS. 11

9

Figure 5. Surface expression of P-ARs by RA W264.7 macrophage in response to LPS activation and NE treatment.
RA W264. 7 macrophages were plated in wells containing sterile glass coverslips. Cells were treated with l µM NE,
then activated with 100 ng/ml LPS and incubated for 4 hours. Mouse anti-P-AR antibody was used as primary
antibody, and anti-mouse IgG-AlexaFluor conjugated antibody was used as the secondary antibody.
Immunofluorescence images were collected using Leica Confocal Software with a Leica SP2 Laser Scanning
Confocal Microscope, and the contrast in transmitted light images was enhanced u ing Adobe Photoshop CS3
Extended software. Red images (Al-C2) were obtained using anti-mouse IgG secondary antibody conjugated with
AlexaF\uor 647; Green images (Al '-C2') were obtained using anti-mouse IgG secondary antibody conjugated with
AlexaFluor 594. Al A2 A I ' A2' represent resting RA W264.7 macrophages ; BI, B2, Bl ', B2' represent
RA W264 .7 macrophages activated with I00ng/ml LPS; Cl, C2, Cl', C2' represent RAW264 .7 macrophages
activated with I00ng/ml LPS and treated with lµM NE

Regulation of urface expression of a-adrenergic receptor. by LPS activation and NE expo ure
Studies were also performed to characterize the surface expression of a,-ARs in response
to LPS activation and E exposure. Immunofluorescence was performed using mouse anti-u-AR
primary antibody and anti-mouse TgG-AlexaFluor594 conjugated secondary antibody . All
images were collected using confocal microscopy. Controls were again performed to
demonstrate that the antibodies used were specific to their advertised epitopes and to control for
autofluorescence of the RA W264.7 cells (data not shown).
Immunofluorescence reveals that quiescent RA W264.7 macrophages express extremely
low levels of o.-ARs on their surface. This pattern is characterized by very low intensity staining,
and widely dispersed points of fluorescence (Figure 6 Al-2). Activation with LPS noticeably
increases the intensity of surface staining, as well as the number of points emitting fluorescence.
This indicates that activated macrophages increase the expression of a,-ARs on their surfaces
(Figure 6 B 1- B2). Treatment with E appears to result in a slight decrease in the amount and
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intensity of fluorescence, indicating a slight decrease in a-AR expression (Figure 6 Cl-2).
However, more quantitative immunofluorescence studies are needed to determine if this apparent
change represents a significant decline.
Most images are collected at the surface of the cells to best demonstrate visible changes
in AR expression. Optical sectioning through the center of a cell reveals a distinctive ring of
fluorescence around the perimeter of a cell, and that staining is generally specific to the plasma
membrane of RA W264.7 macrophages. This indicates that changes seen in the
immunofluorescence studies reflect changes in surface protein expression, rather than global
changes in protein expression throughout the cell (Figure 6 D1-2).

Figure 6. Surface expression of <I-ARs by RA W264 .7 macrophages in response to LPS activation and NE treatment.
RA W264 .7 macrophages were plated in wells containing sterile glass coverslips . Cells were treated with lµM NE ,
then activated with I 00 ng/ml LPS and incubated for 4 hours. Mouse anti-<I-ARantibody was used as primary
antibody, and anti-mouse IgG-AlexaFluor 594 conjugated antibody was used as the secondary antibody.
Immunofluorescence images were collected using Leica Confocal Software with a Leica SP2 Laser Scanning
Confocal Microscope , and the contrast in transmitted light images was enhanced using Adobe Photoshop CS3
Extended software. Al , A2 represent resting macrophages ; B 1, B2 represent RA W264 .7 macrophages activated
with 100 ng/ml LPS; Cl , C2, D 1, D2, represent RA W264. 7 macrophages activated with I 00 ng/ml LPS and treated
with lµMNE.
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Discussion
This study was designed to characterize the expression patterns of a- and i1-ARs, and the
role they play in regulating RA W264. 7 macrophage activity. This cell line is commonly used as
a model of macrophage behavior, but much of the research regarding catecholamine-mediated
regulation of macrophages has been performed with primary macrophages. Given the relevance
of RA W264. 7 macrophages as a model, it is important to understand their regulation. This data
indicates that signaling through the P-AR decreases macrophage function, and it is thus in
agreement with most previous studies. 3•11•14•17•18 Cytokine secretion, a common measure used to
represent the immunological activity level of macrophages, was significantly decreased after
treatment with NE or FOM, a P-AR agonist. B-ARs are also strongly expressed in quiescent
macrophages, and their surface expression decreases in response to LPS activation of the
macrophages.
Conversely, a-AR surface expression is extremely low in quiescent macrophages, but
noticeably increases after LPS activation. NE treatment also appears to slightly decrease a-AR
surface expression on activated macrophages. While the changes in surface expression of a-ARs
appear relatively straightforward, the role of a-ARs in regulating macrophage immunological
activity has yet to be fully characterized. This research suggests that enhancement of cytokine
secretion by catecholamines is mediated through a-ARs, as antagonizing the receptors abrogated
this effect. However, TNF studies exhibited both an enhancement and a decline in cytokine
secretion after treatment with the a-AR agonist. These results suggest that changes in a-AR
surface expression may alter the regulation of cytokine secretion. Additionally, some changes in
expression may be due to conditions that have yet to be clearly defined.
Macrophages are cellular mediators of innate immunity, and play an essential role in
maintaining health. To carry out this function, macrophages must be capable ofresponding to
PAMPs displayed in MHCs and free in the extracellular matrix. Additionally, the body must
carefully regulate these cells to avoid over-activity or excessive suppression, both of which can
result in disease states. 1 Recent research has demonstrated that macrophages are regulated by
direct immunological signals as well as neuroendocrine signaling via catecholamines.
Catecholamines regulate inflammatory response behavior in macrophages by binding to surface
ARs, initiating signaling cascades that are hypothesized to alter macrophage function. Current
research indicates that stimulation of these two ARs tends to have different, if not opposite,
effects on macrophages. 15 In this study, strong evidence was found to support a negative effect
on immunological activity by the ~-AR stimulation. However, the role of the a-AR remains more
elusive.
In the body, NE can bind to both a- and P-ARs to alter immunological function of
macrophages. The preference for one type of AR over the other has been shown to be
concentration dependent, with high concentrations of NE inducing a predominantly P-AR effect.
The results shown here support this model, as decreases in TNF secretion were seen as a result of
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NE treatment (Figure 1). However, at very low concentrations, NE binds predominantly to the
higher affinity a-AR and can enhance immunological function. 3 •15•16•18 Epinephrine treatment
similarly produces a predominantly f3-ARresponse, enhancing the production of antiinflammatory cytokines such as IL-10 as well as down-regulating pro-inflammatory cytokine
production in LPS-activated primary macrophages. 13•18
Kizaki et al. recently proposed a model detailing the cross-talk between the TLR4/LPS
pathway and the P-AR pathway. Their study demonstrated that stimulation of P2-ARs decreases
the degradation oflKBa in the cytoplasm of macrophages. This effect is mediated by a direct
interaction between IKBa and P-arrestin 2, a protein that is activated by the f32-AR signaling
cascade. This interaction stabilizes IKBa, and thus prevents the release of NF-KB from the
complex. Lower NF-KB release ultimately results in lower levels of this transcription factor in
the nucleus, and less transcription of pro-inflammatory genes in response to the TLR4 activation
signal. 11 The results of these ELISA studies with the P-AR agonist FOM strongly support the
model that J3-ARstimulation decreases cytokine release. According to the model proposed by
Kazaki et al. it would appear that this decrease is a result of decreased transcription of cytokine
genes. 11 However, further study is necessary to conclusively show that decreases in secreted
cytokine concentrations are a result of transcriptional regulation.
The immunofluorescence data which details surface expression of P-ARs offers a
possible explanation for how the body may minimize the influence of P-ARs on macrophage
function during an infection. High levels of P-ARs are expressed on the surface of resting
RA W264.7 macrophages, and that surface expression decreases in response to LPS activation
(Figure 5). Down-regulation of P-AR expression reduces the quantity of negative signals that can
be sent to the macrophage. With fewer P-ARs expressed, less signal will be sent and thus less Parrestin 2 will be activated. This will allow for the degradation oflKBa, releasing more NF-KB to
enter the nucleus of activated RA W264. 7 macrophages. Higher levels of pro-inflammatory genes
will then to be produced, leading to a more efficient response to infection. 11 Down regulation of
P-ARs would also thus prevent attenuation of the immune response before the pathogen is
completely cleared from the organism. Additionally, signaling through P-ARs might be a
mechani~m to reduce the level of TNF secretion that causes serious injury during acute sepsis. 18
These studies help to explain how f3-ARs influence macrophage regulation, as well as a potential
reason for this pattern of regulation, but further research is needed to understand the mechanism
regulating expression of J3-ARs.
Immunofluorescence images studying the a-AR also suggest a potential functional
explanation for the documented expression pattern of a-ARs when combined with the current
model of catecholamine effects on macrophage function. 6•19 Resting macrophages express very
low levels of a-ARs on their surfaces, which may be a mechanism for preventing improper
activation of the macrophages. Previous work with macrophages is in agreement with these
results. RT-PCR studies demonstrate that resting macrophages express a 1-AR transcripts at
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undetectable levels, but that transcripts then become detectable after activation with LPS. 10 These
low levels, coupled with the high level of ~-AR expression, might be maintained to ensure that
any catecholamines present will signal predominantly through ~-ARs when no pathogen is
present and the macrophages have not been activated, ensuring that the macrophages remain
inactive. When macrophages become activated, there is a noticeable increase in a-AR
expression. This increase alters the balance between a- and ~-ARs, increasing the likelihood of
catecholamines binding to a-ARs. This change in expression may function as a mechanism to
establish a positive feedback loop. \Vith higher expression of a-ARs, more stimulatory signals
will be sent to the macrophage. This may result in a subsequent enhancement of macrophage
function, and increased efficiency of pathogen clearance. 19
Treatment with NE appears to induce a slight decrease in surface expression of a-ARs.
As NE predominantly signals through ~-ARs, this suggests that there may be some cross-talk
occurring between the two AR pathways that regulates the expression of the a-AR. 1s However,
previous studies with THP-1 monocytes have shown that treatment with a ~2-AR agonist
enhances the amount of a 1-AR transcript in the monocytes. 1 Further study is therefore necessary
to identify the pathway involved in this cross-talk, and to determine its outcome. Current work is
also continuing with characterizing a-AR expression through flow cytometry and western
immunoblotting analysis. As with the ~-AR, additional studies are needed to fully understand
how a-AR surface expression changes in response to exposure to pathogens (LPS activation) and
exposure to catecholamines.

°

The majority of studies have found that stimulation of a-ARs enhances immunological
activity of macrophages. 6' 1s,I 9 Spengler et al. showed that treatment ofLPS-activated
macrophages with UK-14304, a different a-AR agonist, resulted in an increase in TNF mRNA
levels and secreted TNF levels. 1s Treatment with the a-AR antagonist yohimbine suppresses the
normal increase in iNOS expression, and thus NO production, in macrophages activated with
LPS. This indicates that the enhancing effects are a direct result of stimulation of a-ARs. 8 The
results of our studies demonstrate an increase in IL-6 production after a-AR stimulation, in
agreement with these previous studies showing that a-AR signaling enhances macrophage
function. However, not all of our results support the conclusion that stimulation of the a-AR
enhances cytokine secretion. Specifically, the production of TNF was reduced by activated
macrophages after exposure to the a-AR agonist clonidine. Likewise, some previous studies have
found that stimulation of a-ARs is not involved in enhancing cytokine production or, in some
cases, actually decreases macrophage function. 7•14
These variable results may be explained by differences in the expression patterns of a-AR
sub-types on the surface of macrophages during an immune response (LPS activation). Previous
work has shown that macrophages express a 1- and a 2-ARs, and that only stimulation of a 2-ARs
enhances macrophage immunological function. 6•19 However, these sub-types have some
overlapping agonist affinities, and stimulation of both sub-types may contribute to the variable
14

results since clonidine is a general a-AR agonist. 10 Additionally, macrophage a 2 -ARs have also
been shown to have both high and low affinity catecholamine binding sites. Similar sites on
neutrophils have been shown to initiate different signaling cascades when bound. At high
concentrations the agonist binds to the low affinity site, while at lower concentrations
(approximately 1 nM) the agonist binds to the high affinity site. The intermediate concentrations
of clonidine used for these experiments may be stimulating both sites, and producing inconsistent
cytokine secretion. Alternatively, high concentrations of clonidine have been shown to lead to
non-specific binding to other surface receptors. Non-specific binding by clonidine to the ~-AR
may also explain the measured decreases in TNF secretion. 15 Further study elucidating the
signaling pathways initiated by a-AR stimulation might provide a better understanding of the aAR signaling pathway in macrophages.
Despite these inconsistencies, studies with the a-AR antagonist RS79948 indicate that the
stimulatory effects of clonidine are a result of signaling through the a-AR pathway, as addition
of the antagonist abrogated this effect. Measurements of cytokine secretion show that addition of
the antagonist reduced both TNF and IL-6 levels to below that of RA W264.7 macrophages
treated only with LPS (Figure 4). A similar decrease in IL-I~ secretion to below baseline levels
was seen when LPS-activated macrophages were treated with the a-AR antagonist yohimbine in
previous studies. 4 Previous work has shown that macrophages produce the catecholamines NE
and epinephrine in response to LPS treatment. This suggests that these macrophage-derived
catecholamines may act in an autocrine manner to further enhance inflammatory functions
through a-AR signaling in the macrophage. Loss of this autocrine signaling by antagonism of aARs thus results in lower levels of cytokine production than those measured for RA W264. 7
macrophages treated with just LPS due to the loss of the positive feedback loop. Alternatively,
autocrine signaling with the macrophage-produced cytokines may also decrease the
inflammatory response via signaling through exclusively ~-ARs, as the a-ARs are blocked by the
antagonist. 2 ' 15
The results of this study support the current model that neuroendocrine signaling plays an
essential role in regulating immune function. This regulation has been shown to be the result of
interactions between catecholamines and the ARs expressed on the surface of macrophages. It
appears that the sympathetic nervous system can enhance immune function through a-ARs. 19
However, as NE is shown to have a predominately negative effect on cytokine secretion, it
appears more likely that neuroendocrine signaling acts as an additional signal to reduce the
strength of the immune response to protect the host from excessive damage. 18 With more
research, the regulatory power of macrophage-expressed ARs may be used therapeutically to
artificially enhance or shut down the immune system.
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